CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

NCT04626739 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions

DRUG: CD19 CAR-T
DRUG: CD22 CAR-T
DRUG: CD19+CD22 CAR-T
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.